SCHEMBL150770

SCHEMBL150770

CC(C)C(=O)Nc1ccc2c(c1)[nH]c1ccccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.62
KMT2A Q03164 5/20 0.58
KDM4E B2RXH2 3/20 0.58
MTNR1A P48039 1/20 0.58
MTNR1B P49286 1/20 0.58
MEN1 O00255 3/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
NPC1 O15118 1/20 0.58
GAA P10253 1/20 0.58
KIF11 P52732 3/20 0.51
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
RXFP1 Q9HBX9 1/20 0.50
LMNA P02545 1/20 0.50
HDAC8 Q9BY41 1/20 0.48
GLA P06280 1/20 0.48
HPGD P15428 1/20 0.48
HTT P42858 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4729158 0.91 KMT2A (0.71) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL22616930 0.83 MAOA (0.86) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL147687 0.83 MAOA (0.59) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL148199 0.82 SMN1; SMN2 (0.61) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL3696476 0.81 MAOA (0.64) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL22616916 0.79 MAOA (0.62) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL14369937 0.78 KDM4E (0.53) MAOAKMT2AKDM4EMEN1RAB9A
SCHEMBL148317 0.75 P2RY12 (0.63) MAOAKMT2AKDM4EMTNR1AMTNR1B
SCHEMBL20887144 0.75 TP53 (0.61) KDM4EMAPTHTT
SCHEMBL147307 0.74 ROCK2 (0.73) MAOAKMT2AKDM4EMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362065-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2013-01-29 US disclosed
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-8084620-B2 Carbazole carboxamide compounds useful as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2011-12-27 US disclosed
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058996-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 MAOA 3150/4885KMT2A 561/4885KDM4E 733/4885
US-20100160303-A1 CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BTK, FLT3, JAK1 MAOA 3150/4885KMT2A 561/4885KDM4E 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.